NASDAQ$VERA
Vera Therapeutics Inc · Q2 2025 earnings
Q2 2025 earnings · · Before market open · Investor relations
Briefing
Vera Therapeutics Inc reported a net loss of $76.5 million for the second quarter of 2025.
Vera Therapeutics, a clinical-stage biotechnology company, continued advancing its lead candidate atacicept in IgAN with positive Phase 3 data supporting planned regulatory submission. The company reported increased R&D and G&A expenses driven by clinical development and pre-commercial activities, resulting in a larger quarterly net loss compared to the prior year. Cash position remained strong at $556.8 million including marketable securities to fund ongoing operations.
- Net loss widened to $76.5 million for Q2 2025 from $33.7 million in Q2 2024 due to higher operating expenses.
- R&D expenses rose 99% year-over-year to $58.2 million, primarily from contract manufacturing and clinical trial costs for atacicept.
- Completed full enrollment of ORIGIN 3 Phase 3 trial and announced primary endpoint results supporting Q4 2025 regulatory submission.
- Maintained robust liquidity with $556.8 million in cash, cash equivalents, and marketable securities as of June 30, 2025.
Headline financials
Revenue & EPS history
Vera · Revenue · Quarterly
-$337K
Forward guidance
Company plans to submit regulatory approval application for atacicept in IgAN in Q4 2025 based on positive Phase 3 data.
Tailwinds
- Strong cash position supports continued development and pre-commercial activities.
- Breakthrough Therapy Designation maintained for atacicept in IgAN.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports
+0.2%
Avg return
Earnings day
+2.3%
Avg return
5 days after
+7.2%
Avg return
30 days after
55%
11 / 20 earnings
Positive
+15.6%
Q1 2022
Best reaction
-13.5%
Q1 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2025 | — | — | — | |
| Q1 2026 | -2.0% | +0.3% | -11.8% | |
| Q4 2025 | +1.5% | -5.7% | -6.8% | |
| Q3 2025 | +4.6% | +23.3% | +86.3% | |
| Q1 2025 | -13.5% | -15.0% | +20.0% | |
| Q4 2024 | +1.3% | -0.7% | -22.1% | |
| Q3 2024 | +0.3% | +1.3% | +1.1% | |
| Q2 2024 | +0.9% | +6.5% | +4.3% | |
| Q1 2024 | -8.1% | -9.1% | -14.3% | |
| Q4 2023 | -1.3% | -5.2% | -12.5% | |
| Q3 2023 | +5.4% | +18.2% | +18.9% | |
| Q2 2023 | -0.1% | -4.3% | -0.1% | |
| Q1 2023 | -1.7% | +0.0% | +0.9% | |
| Q4 2022 | +4.4% | +6.3% | -14.2% | |
| Q3 2022 | -3.2% | -3.8% | -2.1% | |
| Q2 2022 | +7.8% | +20.6% | +11.4% | |
| Q1 2022 | +15.6% | +11.4% | -8.5% | |
| Q4 2021 | +10.2% | +11.2% | +5.2% | |
| Q3 2021 | -11.6% | -7.1% | -3.3% | |
| Q2 2021 | +0.3% | +11.6% | +80.6% | |
| Q1 2021 | -7.6% | -13.6% | +11.0% | |
| Q4 2020 | — | — | — | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro